Neuroleptic-induced hyperprolactinemia

Schizophrenia Research

Volumn 35, Issue SUPPL., 1999, Pages

  Dickson, Ruth A ^a   Glazer, William M ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Clozapine; Galactorrhea; Neuroleptic induced hyperprolactinemia; Neuroleptics; Olanzapine; Prolactin; Quetiapine; Risperidone; S chizophrenia

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE;

BREAST CARCINOMA; CARDIOTOXICITY; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; GALACTORRHEA; HUMAN; HYPERPROLACTINEMIA; HYPOGONADISM; MENSTRUAL IRREGULARITY; OSTEOPOROSIS; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DYSKINESIA, DRUG-INDUCED; FEMALE; FERTILITY; HUMANS; HYPERPROLACTINEMIA; HYPOGONADISM; MALE; OSTEOPOROSIS; PROLACTIN; SCHIZOPHRENIA; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE;

EID: 0033105824     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00159-5     Document Type: Conference Paper

References (89)

1. Abraham G., Friedman R.H., Verghese C., de Leon J. Osteoporosis and schizophrenia: can we limit known risk factors? Soc. Biol. Psychiatry. 38:1995;2.
2. Aizenberg D., Zemishlany Z., Dorfman-Etrog P., Weizman A. Sexual dysfunction in male schizophrenic patients. J. Clin. Psychiatry. 56:1995;137-141.
3. American Psychiatric Association, 1997. Practice guideline for the treatment of patients with schizophrenia. Am. J. Psychiatry 154 (Suppl. 4), 1-63.
4. Arvanitis L.A., Miller B.G. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol. Psychiatry. 42:1997;233-246.
5. Ataya K., Mercado A., Kartaginer J., Abbasi A., Kamran S.M. Bone density and reproductive hormones in patients with neuroleptic-induced hyperprolactinemia. Fertil. Steril. 50:1988;876-881.
6. Barnes T.R., Bamber R.W., Watson J.P. Psychotropic drugs and sexual behaviour. Br. J. Hosp. Med. 21:1979;594-600.
7. Beasley C., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 14:1996;111-123.
8. Beasley C., Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 124:1996;159-167.
9. Bernstein L., Ross R.K. Endogenous hormones and breast cancer risk. Epidemiol. Rev. 15:1993;48-65.
10. Beumont P.J., Corker C.S., Friesen H.G.et al. The effects of phenothiazines on endocrine function-II. Effects in men and post-menopausal women. Br. J. Psychiatry. 124:1974;420-430.
11. Biller B.M.K., Baum H.B.A., Rosenthal D.I., Saxe V.C., Charpie P.M., Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J. Clin. Endocrinol. Metab. 75:1992;692-697.
12. Buckman, M.T., 1985. Psychological distress in hyperprolactinemic women. In: MacLeod, R.M., Thorner, M.O., Scapagnini, U. (Eds.), Prolactin: Basic and Clinical Correlates. Liviana Press, Padova, Italy, pp. 601-608.
13. Bunker M.T., Marken P.A., Schneiderhan M.E., Ruehter V.L. Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. J. Child Adolesc. Psychopharmacol. 7:1997;65-69.
14. Chouinard G., Jones B., Remington B., Bloom W., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnott W. A Canadian multicentre placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:1993;25-40.
15. Conference Report, 1991. Consensus development conference: prophylaxis and treatment of osteoporosis. Osteoporos. Int. 1, 114-117.
16. Corenblum, B., 1990. Galactorrhea and hyperprolactinemia. Med. Clin. North Am. November, 1569-1579.
17. Corenblum, B., 1993. Disorders of prolactin secretion. In: Copeland, L.J. (Ed.), Textbook of Gynecology. W.B. Saunders, Philadelphia, pp. 447-467.
18. Corenblum B. Rise above normal when treating hyperprolactinemia. Can. J. Diagnosis. 14:1997;133-144.
19. Crawford A.M.K., Beasley C.M. Jr., Tollefson G.D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr. Res. 28:1997;224-267.
20. Crenshaw, T.L., Goldberg, J.P., 1996. Sexual Pharmacology: Drugs That Affect Sexual Functioning. W.W. Norton, New York, pp. 307-316.
21. Currier G.W., Simpson G.M. Antipsychotic medications and fertility. Psychiatr. Serv. 49:1998;175-176.
22. Dickson R.A., Dalby J.T., Williams R., Edwards A.L. Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Letter. Am. J. Psychiatry. 152:1995;1102-1103.
23. Dickson R.A., Edwards A. Clozapine and fertility. Letter. Am. J. Psychiatry. 154:1997;582-583.
24. Dickson R.A., Dawson D.T. Olanzapine and pregnancy. Letter. Can. J. Psychiatry. 43:1998;196-197.
25. Dickson R.A., Hogg L. Pregnancy of a patient treated with clozapine. Psychiatr. Serv. 49:1998;1081-1083.
26. English K.M. Testosterone and coronary artery disease: is there a link? Q. J. Med. 90:1997;787-791.
27. Fava G.A., Fava M., Kellner R., Serafini E., Mastrogiacomo I. Depression hostility and anxiety in hyperprolactinemic amenorrhea. Psychother. Psychosom. 36:1981;122-128.
28. Ferrier I.N., Cotes P.M., Crow T.J., Johnstone E.C. Gonadotropin secretion abnormalities in schizophrenia. Psychol. Med. 12:1982;263-273.
29. Fink G.et al. Estrogen control of central neurotransmission: effect on mood, mental state and memory. Cell. Mol. Neurobiol. 16:1996;325-344.
30. Forman, R., Gilmour-White, S., Forman, N., 1996. Sexual and reproductive function. In: Drug-Induced Fertility and Sexual Dysfunction. Cambridge University Press, Cambridge, United Kingdom, pp. 1-14.
31. Ghadirian A.M., Chouinard G., Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J. Nerv. Ment. Dis. 170:1982;463-467.
32. Glazer W.M., Moore D.C., Bowers M.B. Jr., Brown W.A. Serum prolactin and tardive dyskinesia. Am. J. Psychiatry. 138:1981;1493-1496.
33. Glazer W., Naftolin F., Morgenstern H., Barnea E.R., MacLusky N.J., Brenner L.M. Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology. 10:1985;345-350.
34. Glazer, W., Nasrallah, H., 1988. Neuroendocrine aspects of tardive dyskinesia: The role of estrogen, prolactin, and dopamine. In: Wolfe, M.E., Moisnaim, A.D. (Eds.), Tardive Dyskinesia: Biological Mechanisms and Clinical Aspects. APA Press, Washington, DC, pp. 179-196.
35. Goodwin P.J. Breast cancer risk in psychiatric patients. Letter. Am. J. Psychiatry. 154:1997;588.
36. Gregory B.A.J.C. The menstrual cycle and its disorders in psychiatric patients-II. J. Psychosom. Res. 2:1957;199-224.
37. Halbreich U., Rojansky N., Palter S., Hreshchyshyn M., Kreeger J., Bakhai Y., Rosan R. Decreased bone mineral density in medicated psychiatric patients. Psychosom. Med. 57:1995;485-491.
38. Halbreich U., Palter S. Accelerated osteoporosis in psychiatric patients: possible pathophysiological processes. Schizophr. Bull. 22:1996;447-454.
39. Halbreich U., Shen J., Panaro V. Are chronic psychiatric patients at increased risk for developing breast cancer? Am. J. Psychiatry. 153:1996;559-560.
40. Jeffries J.J., Vanderhaeghe L., Remington G.J., al-Jeshi A. Clozapine-associated retrograde ejaculation. Letter. Can. J. Psychiatry. 41:1996;61-63.
41. Kaplan B., Modai I., Stoler M., Kitai E., Valevski A., Weizman A. Clozapine treatment and risk of unplanned pregnancy. J. Am. Board Fam. Pract. 8:1995;239-241.
42. Kartaginer J., Ataya K., Mercado A., Abbasi A. Osteoporosis associated with neuroleptic treatment - a case report. J. Reprod. Med. 35:1990;198-202.
43. Katz J., Kunofsky S., Patton R.E., Allaway N.C. Cancer mortality among patients in New York mental hospitals. Cancer. 20:1967;2194-2199.
44. Keeley E.J., Reiss J.P., Drinkwater D.T., Faiman C. Bone mineral density, sex hormones, and long-term use of neuroleptic agents in men. Endocr. Pract. 3:1997;209-213.
45. Klawans H. Jr. The pharmacology of tardive dyskinesia. Am. J. Psychiatry. 130:1973;82-86.
46. Kulkarni J., de Castella A., Smith D., Taffe J., Keks N., Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizophr. Res. 20:1996;247-252.
47. Kuruvilla A., Peedicayil J., Srikrishna G., Kuruvilla K., Kanagasabapathy A.S. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin. Exp. Pharmacol. Physiol. 19:1992;603-606.
48. Lindamer L.A., Lohr J.B., Harris M.J., Jeste D.V. Gender, estrogen, and schizophrenia. Psychopharmacol. Bull. 33:1997;221-228.
49. Magrini G., Gasperi M., Martin-du Pan R., Baumann P., Felber J.P. Effects of chronic neuroleptic therapy on human PRL secretion and testicular function. Arch. Androl. 6:1981;219-228.
50. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 151:1994;825-835.
51. Marken P.A., Haykal R.F., Fisher J.N. Management of psychotropic-induced hyperprolactinemia. Clin. Pharmacol. 11:1992;851-856.
52. Martin-du Pan R., Baumann P., Magrini G., Felber J.-P. Neuroendocrine effects of chronic neuroleptic therapy in male psychiatric patients. Psychoneuroendocrinology. 3:1979;245-252.
53. McEwen B.S. Ovarian steroids and the brain: implications for cognition and aging. Neurology. 48(Suppl. 7):1997;S8-S15.
54. Melmed, S. (Ed.), 1995. The Pituitary. Blackwell Science, Cambridge, MA, pp. 149-162.
55. Meltzer H.Y., Goode D.J., Schyve P.M., Young M., Fang V.S. Effect of clozapine on human serum prolactin levels. Am. J. Psychiatry. 136:1970;1550-1555.
56. Merkatz R.B., Temple R., Sobel S., Feiden K., Kessler D.A. Women in clinical trials of new drugs: a change in Food and Drug Administration policy. The Working Group on Women in Clinical Trials. N. Engl. J. Med. 329:1993;292-296.
57. Mortensen P.B. The incidence of cancer in schizophrenic patients. J. Epidemiol. Community Health. 12:1989;185-194.
58. Mortensen P.B. The occurrence of cancer in first admitted schizophrenia patients. Schizophr. Res. 12:1994;185-194.
59. Mortensen P.B. Breast cancer risk in psychiatric patients. Am. J. Psychiatry. 154:1997;589.
60. Murphy W.J., Rui H., Longo D.L. Effects of growth hormone and prolactin on immune development and function. Life Sci. 57:1995;1-14.
61. Overall J.E. Prior psychiatric treatment and the development of breast cancer. Arch. Gen. Psychiatry. 35:1978;898-899.
62. Riecher-Rössler A., Hafner H., Stumbaum M., Maurer K., Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr. Bull. 20:1994;203-214.
63. Rosenheck R., Cramer J., Xu W., Henderson T.J., Frisman L., Fye C., Charney D. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Group Study on Clozapine in Refractory Schizophrenia. N. Engl. J. Med. 337:1997;809-815.
64. Rubin R.T., Poland R.E., Tower B.B. Prolactin-related testosterone secretion in normal adult men. J. Clin. Endocrinol. Metab. 42:1976;112-116.
65. Rubin, R.T., 1987. Prolactin and schizophrenia. In: Meltzer, H.Y. (Ed.), Psychopharmacology: The Third Generation of Progress. Raven Press, New York, pp. 803-808.
66. Rubinow D.R., Schmidt P.J. Androgens, brain, and behavior. Am. J. Psychiatry. 153:1996;974-984.
67. Santoni J.Ph., Saubadu S. Adverse events associated with neuroleptic drugs: focus on neuroendocrine reactions. Acta Ther. 21:1995;193-204.
68. Schlechte J., Walkner L., Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J. Clin. Endocrinol. Metab. 75:1992;698-703.
69. Schumucker D.L., O'Mahoney M.S., Vessell E.S. Women in clinical drug trials: an update. Clin. Pharmacokinet. 27:1994;411-417.
70. Seeman M.V., Lang M. The role of estrogens in schizophrenia: gender differences. Schizophr. Bull. 16:1990;185-194.
71. Seeman M.V. The role of estrogen in schizophrenia. J. Psychiatry Neurosci. 21:1996;123-127.
72. Seeman M.V. Psychopathology in men and women: focus on female hormones. Am. J. Psychiatry. 154:1997;1641-1647.
73. Segraves R.T. Male sexual dysfunction and psychoactive drug use. Review of a common relationship. Postgrad. Med. 71:1982;227-233.
74. Segraves R.T. Effects of psychotropic drugs on human erection and ejaculation. Arch. Gen. Psychiatry. 46:1989;275-284.
75. Shaarawy M., Nafei S., Abul-Nasr A., el-Sharkawy S., Younis A. Circulating nitric oxide levels in galactorrheic, hyperprolactinemic, amenorrheic women. Fertil. Steril. 68:1997;454-459.
76. Sherwin B.B. Estrogen effects on cognition in menopausal women. Neurology. 48(Suppl. 7):1997;S21-S26.
77. Smith S. Neuroleptic-associated hyperprolactinemia: can it be treated with bromocriptine? J. Reprod. Med. 37:1992;737-740.
78. Sobrinho L. The psychogenic effects of prolactin. Acta Endocrinol. (Copenh). 129(Suppl. 1):1993;38-40.
79. Stampfer M.J., Colditz G.A., Willett W.C. Menopause and heart disease: a review. Ann. N.Y. Acad. Sci. 592:1990;193-203.
80. Tollefson G.D., Beasley C.M. Jr., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.A. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry. 154:1997;457-465.
81. Torrey E.F. Breast cancer risk in psychiatric patients. Letter. Am. J. Psychiatry. 154:1997;588-589.
82. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley C. Jr., Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 17:1997;407-418.
83. Vance M.L. New directions in the treatment of hyperprolactinemia. The Endocrinologist. 7:1997;153-159.
84. Villeneuve A., Cazejust T., Cote M. Estrogens in tardive dyskinesia in male psychiatric patients. Neuropsychobiology. 6:1980;145-151.
85. Wagner S., Mantal N. Breast cancer at a psychiatric hospital before and after the introduction of neuroleptic agents. Cancer Res. 38:1978;2703-2708.
86. Waldman M.D., Safferman A. Pregnancy and clozapine. Letter. Am. J. Psychiatry. 150:1993;168-169.
87. Wesselmann U., Windgassen K. Galactorrhea: subjective response by schizophrenic patients. Acta Psychiatr. Scand. 91:1995;152-155.
88. Windgassen K., Wesselmann U., Schulze Monking H. Galactorrhea and hyperprolactinemia in schizophrenic patients on neuroleptics: frequency and etiology. Neuropsychobiology. 33:1996;142-146.
89. Winters S.J., Troen P. Altered pulsatile secretion of luteinizing hormone in hypogonadal men with hyperprolactinaemia. Clin. Endocrinol. 21:1984;257-263.